Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 4,395 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Diagnostic Imaging Clear all

Conditions: Cushing Syndrome, Endocrine Disease
Interventions: Pentetreotide, 18F-DOPA, CT scan, MRI, 18-FDG; Drug · Device
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 90 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ovarian Cancer
Interventions: PET/CT Scan, MRI; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 2
States / cities: Harrison, New York • New York, New York

Conditions: Stroke
Interventions: Merci Retriever and Penumbra System; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 85 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 21
States / cities: Los Angeles, California • San Diego, California • Santa Monica, California + 13 more

Conditions: Solid Tumor, Solid Carcinoma, Castration-Resistant Prostate Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Glioma, Malignant
Interventions: 18F-TRX, Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy, Blood Specimen Collection; Drug · Procedure
Lead sponsor: Rahul Aggarwal; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Traumatic Brain Injury, Post Traumatic Stress Disorder
Interventions: RT fMRI, Cognitive Training, Control RT fMRI, Control Cognitive Training; Behavioral
Lead sponsor: Van Boven, Robert W., M.D.; Other
Eligibility: 18 Years to 45 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Fort Hood, Texas

Conditions: Solid Malignancy, Lymphoma
Interventions: [18F] 4-L-Fluoroglutamine (2S,4R); Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years to 90 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Cardiovascular Diseases
Interventions: Incorporation of CT and/or c-MRI derived myocardial scar with 3D electroanatomical mapping (EAM).; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Carcinoma
Interventions: Digital Breast Tomosynthesis (DBT), Scintimammography; Procedure · Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 3,023 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2025
U.S. locations: 5
States / cities: Detroit, Michigan • Rochester, Minnesota • Toledo, Ohio + 2 more

Conditions: Stage I Renal Cell Cancer, Stage II Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions: Arterial Spin Labeling Magnetic Resonance Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Perfusion Magnetic Resonance Imaging; Procedure
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Healthy, Glutamate Receptor, mGlur5 Protein, Excitatory Amino Acid Receptors, Drug Kinetics, PET Scan
Interventions: [18F]SP203; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Trauma, Brain, Neuroinflammation
Interventions: Manual Lymphatic Drainage (MLD); Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: 3-D Optical Surface Scan, Mechanical Testing, Cutaneous Ultrasound, Breast MRI and/or CT; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Alzheimer Disease
Interventions: 18F-MK-6240, Lumbar Puncture (optional); Drug · Procedure
Lead sponsor: Patrick Lao; Other
Eligibility: 50 Years to 100 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Rectal Cancer
Interventions: Metabolic Imaging; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Stanford, California

Conditions: Sudden Cardiac Death
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pelvic Organ Prolapse
Interventions: Pre/post imaging; Other
Lead sponsor: Artann Laboratories; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 5
States / cities: Tampa, Florida • Princeton, New Jersey • Allentown, Pennsylvania + 2 more

Conditions: Osteoarthritis
Interventions: X-ray; magnetic resonance imaging; Radiation
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Patient Education, Virtual Reality, Diagnostic Imaging, Cancer Patient
Interventions: Survey and interview; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Patellofemoral Osteoarthritis, Knee Osteoarthritis, Knee Pain, Inflamation
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Nicotine Dependence
Interventions: Amphetamine; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Oral Squamous Cell Carcinoma (OSCC)
Interventions: Olaparib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Breast Cancer
Interventions: LUM015, LUM 2.6 Imaging Device; Drug · Device
Lead sponsor: Lumicell, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HER2 Negative Breast Cancer
Interventions: Response monitoring (no intervention); Other
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Alzheimer's Disease, Mild Cognitive Impairment
Interventions: florbetapir F 18; Drug
Lead sponsor: Avid Radiopharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 8
States / cities: Scottsdale, Arizona • Tucson, Arizona • Costa Mesa, California + 5 more

Search by objective public record fields.

New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome

Benchmarking Intra-tumor Heterogeneity In Ovarian Cancer: Linking In-vivo Imaging Phenotypes With Histology And Genomics

Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy

Imaging of Solid Tumors Using 18F-TRX

Using Real-Time Functional Brain Imaging to Enhance Recovery From TBI

A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R)

The STandard Versus ImAging SuBstrate Aided Ablation in Severe Left VEntricular Dysfunction VT.

Molecular Breast Imaging and Digital Breast Tomosynthesis in Screening Patients With Dense Breast Tissue

Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors

PET Imaging of Brain mGluR5 Receptors Using [18F]SP203

Imaging Lymphatic/Cerebrospinal Fluid (CSF) Drainage From the Head and Neck in Persons With Traumatic Brain Injury: Demonstration of Feasibility and Evaluation of Manual Therapy to Improve Drainage and Facilitate Cognitive Recovery

3-Dimensional Form and Soft Tissue Biomechanics of the Breast

Imaging Tau in Alzheimer's Disease and Normal Aging

Metabolic Imaging Predict Histopathologic Response to Preop ChemoXRT for Locally Advanced Rectal CA

Imaging Techniques for Identifying Factors of Sudden Cardiac Death Risk

Vaginal Tactile Imaging for Pelvic Floor Prolapse

Weight-Bearing Magnetic Resonance Imaging (MRI) for Analysis of Knee Osteoarthritis (OA)

Virtual Reality in Imaging Review for Cancer Patients

FDG PET/MRI Imaging of Patellofemoral Joint Osteoarthritis

Imaging Extrastriatal Dopamine Release in Tobacco Smokers and Nonsmokers

A Dye for the Detection of Cancer of the Tongue and Mouth

Feasibility Study of Intraoperative Imaging in Breast Cancer

Monitoring Response to Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Using High-speed MR Spectroscopic Imaging

Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)